The rationale for targeting zinc therapy to a copper-related metabolic phenotype derives from a long-standing hypothesis that implicates elevated non-ceruloplasmin copper (also called “free copper” or exchangeable copper [13]) as a contributor to neurotoxicity in AD [9,21]. The gene discussed is CP; the disease is Alzheimer disease.